Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
SAN RAMON, Calif., Sept. 06, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 at The Lotte New York Palace Hotel in New York City. During the presentation, Mr. Rigby will provide an overview and update on the company's business.
Date: Monday, September 12, 2016
Time: 2:35 PM ET
Room: Louis
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected] The Ruth Group David Burke (646) 536-7009 [email protected]
